Advertisement

Aegerion Pharmaceuticals Inc., a lipid disorder treatment firm in Cambridge, has been granted orphan drug designation from the U.S. Food and Drug Administration for its treatment of familial chylomicronemia (FC), a rare genetic disorder.

The drug candidate, lomitapide, is currently in Phase 3 clinical trials to treat Homozygous Familial Hypercholesterolemia (HoFH), a disorder marked by high levels of low-density lipoprotein in the blood. Lomitapide already has orphan drug designation in the U.S. for HoFH.

SOURCE

Advertisement
Advertisement